Laboratory Corp Of America (LH) Debt to Equity (2006 - 2026)
Laboratory Corp Of America (LH) debt to equity from Dec 31, 2006 to Mar 31, 2026. The current Laboratory Corp Of America (LH) debt to equity is 72.57%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Laboratory Corp Of America (LH)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 64.79% | -17.60% |
| 2024 | 78.63% | +22.51% |
| 2023 | 64.18% | +21.35% |
| 2022 | 52.89% | +0.29% |
| 2021 | 52.74% | -14.13% |
| 2020 | 61.42% | -24.34% |
| 2019 | 81.18% | -4.66% |
| 2018 | 85.14% | -14.23% |
| 2017 | 99.26% | -6.23% |
| 2016 | 105.85% | -17.69% |
| 2015 | 128.61% | +19.85% |
| 2014 | 107.31% | -10.89% |
| 2013 | 120.42% | +124.28% |
| 2012 | 53.69% | -39.48% |
| 2011 | 88.72% | -0.02% |
| 2010 | 88.73% | N/A |
| 2010 | 88.73% | +34.02% |
| 2009 | 66.21% | N/A |
| 2009 | 66.21% | -35.06% |
| 2008 | 101.95% | N/A |
| 2008 | 0.00% | N/A |
| 2007 | 0.00% | N/A |
| 2007 | 0.00% | N/A |
| 2006 | 0.00% | N/A |
Comparison Laboratory Corp Of America (LH) debt to equity with competitors
Laboratory Corp Of America (LH) debt to equity is 72.57%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| CRL | Charles River Laboratories International Inc | 0.23% | -99.69% |
| OPK | Opko Health Inc | 0.29% | -99.60% |
| PRPO | Precipio Inc | 0.49% | -99.32% |
| CSTL | Castle Biosciences Inc | 2.18% | -96.99% |
| NTRA | Natera Inc | 4.53% | -93.76% |
| APDN | Applied Dna Sciences Inc | 4.60% | -93.66% |
| DGX | Quest Diagnostics Inc | 6.83% | -90.59% |
| PRPH | ProPhase Labs Inc | 7.54% | -89.62% |
| BLLN | Billiontoone Inc - Class A | 17.80% | -75.47% |
| IDXX | Idexx Laboratories Inc | 28.91% | -60.16% |
| ICLR | Icon Plc | 31.25% | -56.94% |
| WAT | Waters Corp | 31.75% | -56.25% |
| DHR | Danaher Corp | 34.91% | -51.89% |
| MYGN | Myriad Genetics Inc | 35.66% | -50.87% |
| WGS | GeneDx Holdings Corp - Class A | 38.06% | -47.55% |
| NEO | Neogenomics Inc | 40.86% | -43.69% |
| QGEN | Qiagen NV | 43.79% | -39.66% |
| RVTY | Revvity Inc | 44.66% | -38.46% |
| A | Agilent Technologies Inc | 47.11% | -35.08% |
| ADPT | Adaptive Biotechnologies Corp | 60.35% | -16.84% |
| TMO | Thermo Fisher Scientific Inc | 88.65% | +22.16% |
| RDNT | Radnet Inc | 100.55% | +38.56% |
| XGN | Exagen Inc | 158.47% | +118.38% |
| IQV | IQVIA Holdings Inc | 254.51% | +250.72% |
| SHC | Sotera Health Company | 343.50% | +373.36% |
| NOTV | Inotiv, Inc. Common Stock | 532.33% | +633.57% |
| BDSX | Biodesix Inc | 547.55% | +654.54% |